Imaging-Based Characterization of a <i>Slco2b1<sup>(-/-)</sup></i> Mouse Model Using [<sup>11</sup>C]Erlotinib and [<sup>99m</sup>Tc]Mebrofenin as Probe Substrates
Organic anion-transporting polypeptide 2B1 (OATP2B1) is co-localized with OATP1B1 and OATP1B3 in the basolateral hepatocyte membrane, where it is thought to contribute to the hepatic uptake of drugs. We characterized a novel <i>Slco2b1<sup>(-/-)</sup></i> mouse model using po...
Saved in:
Main Authors: | , , , , , , , |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_cc05e363c9f947968ceae48fa5c99dcb | ||
042 | |a dc | ||
100 | 1 | 0 | |a Solène Marie |e author |
700 | 1 | 0 | |a Irene Hernández-Lozano |e author |
700 | 1 | 0 | |a Louise Breuil |e author |
700 | 1 | 0 | |a Charles Truillet |e author |
700 | 1 | 0 | |a Shuiying Hu |e author |
700 | 1 | 0 | |a Alex Sparreboom |e author |
700 | 1 | 0 | |a Nicolas Tournier |e author |
700 | 1 | 0 | |a Oliver Langer |e author |
245 | 0 | 0 | |a Imaging-Based Characterization of a <i>Slco2b1<sup>(-/-)</sup></i> Mouse Model Using [<sup>11</sup>C]Erlotinib and [<sup>99m</sup>Tc]Mebrofenin as Probe Substrates |
260 | |b MDPI AG, |c 2021-06-01T00:00:00Z. | ||
500 | |a 10.3390/pharmaceutics13060918 | ||
500 | |a 1999-4923 | ||
520 | |a Organic anion-transporting polypeptide 2B1 (OATP2B1) is co-localized with OATP1B1 and OATP1B3 in the basolateral hepatocyte membrane, where it is thought to contribute to the hepatic uptake of drugs. We characterized a novel <i>Slco2b1<sup>(-/-)</sup></i> mouse model using positron emission tomography (PET) imaging with [<sup>11</sup>C]erlotinib (a putative OATP2B1-selective substrate) and planar scintigraphic imaging with [<sup>99m</sup>Tc]mebrofenin (an OATP1B1/1B3 substrate, which is not transported by OATP2B1). Dynamic 40-min scans were performed after intravenous injection of either [<sup>11</sup>C]erlotinib or [<sup>99m</sup>Tc]mebrofenin in wild-type and <i>Slco2b1<sup>(-/-)</sup></i> mice. A pharmacokinetic model was used to estimate the hepatic uptake clearance (CL<sub>1</sub>) and the rate constants for transfer of radioactivity from the liver to the blood (<i>k</i><sub>2</sub>) and excreted bile (<i>k</i><sub>3</sub>). CL<sub>1</sub> was significantly reduced in <i>Slco2b1<sup>(-/-)</sup></i> mice for both radiotracers (<i>p</i> < 0.05), and <i>k</i><sub>2</sub> was significantly lower (<i>p</i> < 0.01) in <i>Slco2b1<sup>(-/-)</sup></i> mice for [<sup>11</sup>C]erlotinib, but not for [<sup>99m</sup>Tc]mebrofenin. Our data support previous evidence that OATP transporters may contribute to the hepatic uptake of [<sup>11</sup>C]erlotinib. However, the decreased hepatic uptake of the OATP1B1/1B3 substrate [<sup>99m</sup>Tc]mebrofenin in <i>Slco2b1<sup>(-/-)</sup></i> mice questions the utility of this mouse model to assess the relative contribution of OATP2B1 to the liver uptake of drugs which are substrates of multiple OATPs. | ||
546 | |a EN | ||
690 | |a OATP2B1 | ||
690 | |a drug transporters | ||
690 | |a [<sup>11</sup>C]erlotinib | ||
690 | |a [<sup>99m</sup>Tc]mebrofenin | ||
690 | |a liver | ||
690 | |a imaging | ||
690 | |a Pharmacy and materia medica | ||
690 | |a RS1-441 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Pharmaceutics, Vol 13, Iss 6, p 918 (2021) | |
787 | 0 | |n https://www.mdpi.com/1999-4923/13/6/918 | |
787 | 0 | |n https://doaj.org/toc/1999-4923 | |
856 | 4 | 1 | |u https://doaj.org/article/cc05e363c9f947968ceae48fa5c99dcb |z Connect to this object online. |